These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24739070)

  • 1. A missed opportunity - consequences of unknown levetiracepam pharmacokinetics in a peritoneal dialysis patient.
    Bahte SK; Hiss M; Lichtinghagen R; Kielstein JT
    BMC Nephrol; 2014 Apr; 15():49. PubMed ID: 24739070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Levetiracetam Seizure Prophylaxis in Severe Traumatic Brain Injury.
    Harlan SS; Philpott CD; Keegan SP; Droege ME; Karve AS; Foreman B; Wakefield D; Mueller EW; Sangha K; Ngwenya LB; Courter JD; Desai P; Droege C
    Ann Pharmacother; 2024 Jul; 58(7):705-714. PubMed ID: 37776163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Modeling of Levetiracetam in Pediatric and Adult Patients With Epilepsy by Using Routinely Monitored Data.
    Ito S; Yano I; Hashi S; Tsuda M; Sugimoto M; Yonezawa A; Ikeda A; Matsubara K
    Ther Drug Monit; 2016 Jun; 38(3):371-8. PubMed ID: 26913593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report.
    Company-Albir MJ; Ruíz-Ramos J; Solana Altabella A; Marqués-Miñana MR; Vicent C; Poveda JL
    J Clin Pharm Ther; 2017 Dec; 42(6):774-775. PubMed ID: 28555936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate.
    Fountain NB; Conry JA; Rodríguez-Leyva I; Gutierrez-Moctezuma J; Salas E; Coupez R; Stockis A; Lu ZS
    Epilepsy Res; 2007 Apr; 74(1):60-9. PubMed ID: 17270398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients.
    Spencer DD; Jacobi J; Juenke JM; Fleck JD; Kays MB
    Pharmacotherapy; 2011 Oct; 31(10):934-41. PubMed ID: 21950640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levetiracetam Pharmacokinetics During Continuous Venovenous Hemofiltration and Acute Liver Dysfunction.
    New AM; Nei SD; Kashani KB; Rabinstein AA; Frazee EN
    Neurocrit Care; 2016 Aug; 25(1):141-4. PubMed ID: 26800696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam as a possible contributor to acute kidney injury.
    Spengler DC; Montouris GD; Hohler AD
    Clin Ther; 2014 Aug; 36(8):1303-6. PubMed ID: 24986483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation.
    Nei SD; Wittwer ED; Kashani KB; Frazee EN
    Pharmacotherapy; 2015 Aug; 35(8):e127-30. PubMed ID: 26242293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on levetiracetam in epilepsy.
    Lyseng-Williamson KA
    CNS Drugs; 2011 Oct; 25(10):901-5. PubMed ID: 21936590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of levetiracetam.
    Patsalos PN
    Clin Pharmacokinet; 2004; 43(11):707-24. PubMed ID: 15301575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers.
    Stockis A; Sargentini-Maier ML; Otoul C; Connor A; Wilding I; Wray H
    Clin Ther; 2010 Sep; 32(10):1813-21. PubMed ID: 21194605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures.
    Usery JB; Michael LM; Sills AK; Finch CK
    J Neurooncol; 2010 Sep; 99(2):251-60. PubMed ID: 20146087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis.
    Wieruszewski PM; Kashani KB; Rabinstein AA; Frazee E
    Neurocrit Care; 2018 Apr; 28(2):243-246. PubMed ID: 28828726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Single Oral Dose Extended-Release Levetiracetam in Healthy Cats.
    Barnard L; Barnes Heller H; Boothe DM
    J Vet Intern Med; 2018 Jan; 32(1):348-351. PubMed ID: 29114943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary efficacy of levetiracetam in children.
    Glauser TA; Dulac O
    Epileptic Disord; 2003 May; 5 Suppl 1():S45-50. PubMed ID: 12915341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic model of levetiracetam in Korean neonates with seizures
.
    Jung YS; Lee SM; Park MS; Park K
    Int J Clin Pharmacol Ther; 2018 May; 56(5):217-223. PubMed ID: 29393846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
    Coupez R; Nicolas JM; Browne TR
    Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levetiracetam.
    Nash EM; Sangha KS
    Am J Health Syst Pharm; 2001 Jul; 58(13):1195-9. PubMed ID: 11449876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.